In this study, SAA improved gentamicin-induced AKI and 5/6 Nx-induced CKD, which may be achieved by inhibiting the release of inflammatory factors and alleviating oxidative stress injury, as well as regulating the MAPKs and TGF-β1/smads signaling pathways. The gene discussed is TGFB1; the disease is chronic kidney disease.